Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: Results from an open-label trial

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Vazquez, Jose ^a   Reboli, Annette C ^b   Pappas, Peter G ^c   Patterson, Thomas F ^d   Reinhardt, John ^e   Chin Hong, Peter ^f   Tobin, Ellis ^g   Kett, Daniel H ^h   Biswas, Pinaki ⁱ   Swanson, Robert ⁱ  

^a AUGUSTA UNIVERSITY   (United States)

^b Cooper Medical School of Rowan University ^*  (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^e CHRISTIANA CARE HEALTH SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ALBANY MEDICAL CENTER   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

Anidulafungin; Azole; Candidemia; Step down strategy

Indexed keywords

ANIDULAFUNGIN; FLUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE EFFECTIVENESS; COST CONTROL; DEHYDRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOTENSION; INVASIVE CANDIDIASIS; LENGTH OF STAY; LIVER FUNCTION TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MULTICENTER STUDY; NAUSEA AND VOMITING; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PATHOGEN CLEARANCE; PHASE 4 CLINICAL TRIAL; POST HOC ANALYSIS; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; CANDIDA; CANDIDIASIS; CANDIDIASIS, INVASIVE; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; SOUTH KOREA; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CANDIDIASIS, INVASIVE; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RESEARCH DESIGN; RISK; TREATMENT OUTCOME; UNITED STATES; VORICONAZOLE; YOUNG ADULT;

EID: 84895519333     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-97     Document Type: Article

References (21)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163. 10.1128/CMR.00029-06, 1797637, 17223626.
2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177. 10.1086/378745, 14557960.
4. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547. 10.1086/502581, 16018429.
5. Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, Speelman P. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother 1999, 43:601-606. 10.1093/jac/43.4.601, 10350396.
6. Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. J Manag Care Pharm 2009, 15:S18-S23.
7. Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010, 65:608-618. 10.1093/jac/dkq038, 20179023.
8. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, Koch G, Battegay M, Fluckiger U, Bassetti S. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother 2009, 64:188-199. 10.1093/jac/dkp131, 2692500, 19401304.
9. Nicolau DP. Containing costs and containing bugs: are they mutually exclusive?. J Manag Care Pharm 2009, 15:S12-17.
10. Desai M, Franklin BD, Holmes AH, Trust S, Richards M, Jacklin A, Bamford KB. A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis 2006, 6:94. 10.1186/1471-2334-6-94, 1513579, 16762061.
11. McLaughlin CM, Bodasing N, Boyter AC, Fenelon C, Fox JG, Seaton RA. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: an intervention study. QJM 2005, 98:745-752. 10.1093/qjmed/hci114, 16126741.
12. Denning DW. Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151. 10.1016/S0140-6736(03)14472-8, 14550704.
13. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635.
14. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004, 48:2021-2024. 10.1128/AAC.48.6.2021-2024.2004, 415613, 15155194.
15. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004, 39:770-775. 10.1086/423378, 15472806.
16. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008, 48:304-309. 10.1097/QAI.0b013e31817af47a, 18545153.
17. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482. 10.1056/NEJMoa066906, 17568028.
18. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011, 15:R253. 10.1186/cc10514, 3334804, 22026929.
19. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, rikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(Suppl 7):19-37.
20. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J, Caspofungin Invasive Candidiasis Study Group Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029. 10.1056/NEJMoa021585, 12490683, Caspofungin Invasive Candidiasis Study Group.
21. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008, 46:2620-2629. 10.1128/JCM.00566-08, 2519503, 18579718.